JP2687995B2 - Ｄｎａ配列、組替えｄｎａ分子およびヒト繊維芽細胞インターフェロン様ポリペプチドの製造方法 - Google Patents
Ｄｎａ配列、組替えｄｎａ分子およびヒト繊維芽細胞インターフェロン様ポリペプチドの製造方法Info
- Publication number
- JP2687995B2 JP2687995B2 JP56047361A JP4736181A JP2687995B2 JP 2687995 B2 JP2687995 B2 JP 2687995B2 JP 56047361 A JP56047361 A JP 56047361A JP 4736181 A JP4736181 A JP 4736181A JP 2687995 B2 JP2687995 B2 JP 2687995B2
- Authority
- JP
- Japan
- Prior art keywords
- dna
- ifn
- hfif
- huifn
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 68
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 79
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 75
- 229920001184 polypeptide Polymers 0.000 title claims description 73
- 108020004511 Recombinant DNA Proteins 0.000 title claims description 63
- 102000053602 DNA Human genes 0.000 title claims description 36
- 238000004519 manufacturing process Methods 0.000 title description 22
- 210000002950 fibroblast Anatomy 0.000 title description 20
- 108020004414 DNA Proteins 0.000 claims abstract description 130
- 108090000467 Interferon-beta Proteins 0.000 claims description 164
- 230000000694 effects Effects 0.000 claims description 78
- 238000000034 method Methods 0.000 claims description 73
- 230000001580 bacterial effect Effects 0.000 claims description 58
- 230000014509 gene expression Effects 0.000 claims description 44
- 102000003996 Interferon-beta Human genes 0.000 claims description 30
- 230000001900 immune effect Effects 0.000 claims description 26
- 230000004071 biological effect Effects 0.000 claims description 20
- 241000701959 Escherichia virus Lambda Species 0.000 claims description 11
- 244000005700 microbiome Species 0.000 claims description 10
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 238000003780 insertion Methods 0.000 abstract description 10
- 230000037431 insertion Effects 0.000 abstract description 10
- 238000012217 deletion Methods 0.000 abstract description 8
- 230000037430 deletion Effects 0.000 abstract description 8
- 230000035772 mutation Effects 0.000 abstract description 5
- 230000037429 base substitution Effects 0.000 abstract description 4
- 102100026720 Interferon beta Human genes 0.000 description 133
- 239000013612 plasmid Substances 0.000 description 130
- 210000004027 cell Anatomy 0.000 description 116
- 108090000623 proteins and genes Proteins 0.000 description 113
- 239000012634 fragment Substances 0.000 description 102
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 75
- 108020004999 messenger RNA Proteins 0.000 description 61
- 239000000284 extract Substances 0.000 description 59
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 54
- 238000004458 analytical method Methods 0.000 description 54
- 102000014150 Interferons Human genes 0.000 description 52
- 108010050904 Interferons Proteins 0.000 description 52
- 229940079322 interferon Drugs 0.000 description 52
- 239000000203 mixture Substances 0.000 description 51
- 239000002299 complementary DNA Substances 0.000 description 44
- 241000588724 Escherichia coli Species 0.000 description 39
- 239000002773 nucleotide Substances 0.000 description 39
- 125000003729 nucleotide group Chemical group 0.000 description 39
- 230000000840 anti-viral effect Effects 0.000 description 38
- 108010076504 Protein Sorting Signals Proteins 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 239000000047 product Substances 0.000 description 33
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 32
- 150000001413 amino acids Chemical class 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 28
- 239000011780 sodium chloride Substances 0.000 description 27
- 108090000204 Dipeptidase 1 Proteins 0.000 description 26
- 230000014616 translation Effects 0.000 description 26
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 24
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 24
- 238000009396 hybridization Methods 0.000 description 24
- 102000006635 beta-lactamase Human genes 0.000 description 23
- 230000008569 process Effects 0.000 description 23
- 108091034057 RNA (poly(A)) Proteins 0.000 description 22
- 238000013519 translation Methods 0.000 description 22
- 108091026890 Coding region Proteins 0.000 description 21
- 239000002253 acid Substances 0.000 description 21
- 239000002585 base Substances 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 21
- 238000011282 treatment Methods 0.000 description 21
- 108020004705 Codon Proteins 0.000 description 19
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 19
- 239000011159 matrix material Substances 0.000 description 19
- 210000000349 chromosome Anatomy 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 238000001556 precipitation Methods 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 16
- 239000000499 gel Substances 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 16
- 238000013518 transcription Methods 0.000 description 16
- 230000035897 transcription Effects 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 15
- 241000700605 Viruses Species 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 241001131785 Escherichia coli HB101 Species 0.000 description 14
- 108010047761 Interferon-alpha Proteins 0.000 description 14
- 102000006992 Interferon-alpha Human genes 0.000 description 14
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 14
- 238000010367 cloning Methods 0.000 description 14
- 238000010276 construction Methods 0.000 description 14
- 239000006166 lysate Substances 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 238000011084 recovery Methods 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 238000012512 characterization method Methods 0.000 description 13
- 230000009089 cytolysis Effects 0.000 description 13
- 239000000872 buffer Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 230000009466 transformation Effects 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 108091008146 restriction endonucleases Proteins 0.000 description 11
- 239000005720 sucrose Substances 0.000 description 11
- 239000004098 Tetracycline Substances 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 10
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 230000035939 shock Effects 0.000 description 10
- 229960002180 tetracycline Drugs 0.000 description 10
- 229930101283 tetracycline Natural products 0.000 description 10
- 235000019364 tetracycline Nutrition 0.000 description 10
- 150000003522 tetracyclines Chemical class 0.000 description 10
- 102000003960 Ligases Human genes 0.000 description 9
- 108090000364 Ligases Proteins 0.000 description 9
- 229920002678 cellulose Polymers 0.000 description 9
- 230000000120 cytopathologic effect Effects 0.000 description 9
- 238000000502 dialysis Methods 0.000 description 9
- 238000001962 electrophoresis Methods 0.000 description 9
- 235000017281 sodium acetate Nutrition 0.000 description 9
- 241000894007 species Species 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 241000233866 Fungi Species 0.000 description 8
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 239000001913 cellulose Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- ZBJWWKFMHOAPNS-UHFFFAOYSA-N loretin Chemical compound C1=CN=C2C(O)=C(I)C=C(S(O)(=O)=O)C2=C1 ZBJWWKFMHOAPNS-UHFFFAOYSA-N 0.000 description 8
- 229950010248 loretin Drugs 0.000 description 8
- 238000006386 neutralization reaction Methods 0.000 description 8
- 210000000287 oocyte Anatomy 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 239000001632 sodium acetate Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 230000002155 anti-virotic effect Effects 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 229960003669 carbenicillin Drugs 0.000 description 7
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000003204 osmotic effect Effects 0.000 description 7
- 229920002401 polyacrylamide Polymers 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 7
- 102000004594 DNA Polymerase I Human genes 0.000 description 6
- 108010017826 DNA Polymerase I Proteins 0.000 description 6
- 208000037280 Trisomy Diseases 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000011543 agarose gel Substances 0.000 description 6
- 239000003443 antiviral agent Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000013611 chromosomal DNA Substances 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- -1 phospho Chemical class 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 108010061982 DNA Ligases Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- 229960000318 kanamycin Drugs 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 229930182823 kanamycin A Natural products 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 4
- 102000012410 DNA Ligases Human genes 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 239000007994 TES buffer Substances 0.000 description 4
- 239000007984 Tris EDTA buffer Substances 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 4
- 108091092330 cytoplasmic RNA Proteins 0.000 description 4
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 4
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 4
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000001995 reticulocyte Anatomy 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 210000003771 C cell Anatomy 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000002227 Interferon Type I Human genes 0.000 description 3
- 108010014726 Interferon Type I Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 239000007990 PIPES buffer Substances 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 241000269370 Xenopus <genus> Species 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000012888 bovine serum Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 210000000078 claw Anatomy 0.000 description 3
- 238000013377 clone selection method Methods 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000007639 printing Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000709744 Enterobacterio phage MS2 Species 0.000 description 2
- 241001646716 Escherichia coli K-12 Species 0.000 description 2
- 241000701533 Escherichia virus T4 Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108010028921 Lipopeptides Proteins 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108010034634 Repressor Proteins Proteins 0.000 description 2
- 102000009661 Repressor Proteins Human genes 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000002832 anti-viral assay Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- VIGBIBDAVDHOTP-UHFFFAOYSA-M sodium;ethanol;acetate Chemical compound [Na+].CCO.CC([O-])=O VIGBIBDAVDHOTP-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- AEELXMHQIJJMKP-QWWZWVQMSA-N (2r,3r)-3-sulfanylbutane-1,2,4-triol Chemical compound OC[C@@H](O)[C@H](S)CO AEELXMHQIJJMKP-QWWZWVQMSA-N 0.000 description 1
- GYPCWHHQAVLMKO-XXKQIVDLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(e)-n-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-c-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GYPCWHHQAVLMKO-XXKQIVDLSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- KDELTXNPUXUBMU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid boric acid Chemical compound OB(O)O.OB(O)O.OB(O)O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KDELTXNPUXUBMU-UHFFFAOYSA-N 0.000 description 1
- BNVUDLDBSRAJTD-UHFFFAOYSA-M 2-methyl-1-[(3-nitrophenyl)methoxy]pyridin-1-ium;chloride Chemical compound [Cl-].CC1=CC=CC=[N+]1OCC1=CC=CC([N+]([O-])=O)=C1 BNVUDLDBSRAJTD-UHFFFAOYSA-M 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- SJPSPCODIPFASV-UHFFFAOYSA-N 5-ethyl-6-phenylphenanthridin-5-ium-3,8-diamine;iodide Chemical compound [I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 SJPSPCODIPFASV-UHFFFAOYSA-N 0.000 description 1
- 208000034579 Acute haemorrhagic conjunctivitis Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241001203928 Aethes Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 244000140786 Brassica hirta Species 0.000 description 1
- 101100008046 Caenorhabditis elegans cut-2 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108010073254 Colicins Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010026206 Conalbumin Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- XPYBSIWDXQFNMH-UHFFFAOYSA-N D-fructose 1,6-bisphosphate Natural products OP(=O)(O)OCC(O)C(O)C(O)C(=O)COP(O)(O)=O XPYBSIWDXQFNMH-UHFFFAOYSA-N 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 101100001670 Emericella variicolor andE gene Proteins 0.000 description 1
- 241000617738 Escherichia coli M5 Species 0.000 description 1
- 101100145155 Escherichia phage lambda cIII gene Proteins 0.000 description 1
- 101001035782 Gallus gallus Hemoglobin subunit beta Proteins 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229940121672 Glycosylation inhibitor Drugs 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 101710121996 Hexon protein p72 Proteins 0.000 description 1
- 101001077660 Homo sapiens Serine protease inhibitor Kazal-type 1 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 101150103227 IFN gene Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000001617 Interferon Receptors Human genes 0.000 description 1
- 108010054267 Interferon Receptors Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229920006063 Lamide® Polymers 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- WEDDFMCSUNNZJR-WDSKDSINSA-N Met-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(O)=O WEDDFMCSUNNZJR-WDSKDSINSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010051141 Myeloblastoma Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000008021 Nucleoside-Triphosphatase Human genes 0.000 description 1
- 108010075285 Nucleoside-Triphosphatase Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000139306 Platt Species 0.000 description 1
- 241001310793 Podium Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100025144 Serine protease inhibitor Kazal-type 1 Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000405217 Viola <butterfly> Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- GVBNSPFBYXGREE-CXWAGAITSA-N Visnadin Chemical compound C1=CC(=O)OC2=C1C=CC1=C2[C@@H](OC(C)=O)[C@@H](OC(=O)[C@H](C)CC)C(C)(C)O1 GVBNSPFBYXGREE-CXWAGAITSA-N 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- RNBGYGVWRKECFJ-ZXXMMSQZSA-N alpha-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ZXXMMSQZSA-N 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001064 anti-interferon Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000010455 autoregulation Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- ARQRPTNYUOLOGH-UHFFFAOYSA-N chcl3 chloroform Chemical compound ClC(Cl)Cl.ClC(Cl)Cl ARQRPTNYUOLOGH-UHFFFAOYSA-N 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- BKHZIBWEHPHYAI-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol Chemical compound ClC(Cl)Cl.CC(C)CCO BKHZIBWEHPHYAI-UHFFFAOYSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 101150054175 cro gene Proteins 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 125000003192 dTMP group Chemical group 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000002031 ethanolic fraction Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 108010092809 exonuclease Bal 31 Proteins 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- RNBGYGVWRKECFJ-UHFFFAOYSA-N fructose-1,6-phosphate Natural products OC1C(O)C(O)(COP(O)(O)=O)OC1COP(O)(O)=O RNBGYGVWRKECFJ-UHFFFAOYSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000001320 lysogenic effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000004713 multireference configuration interaction Methods 0.000 description 1
- LCNBIHVSOPXFMR-UHFFFAOYSA-N n'-(3-aminopropyl)butane-1,4-diamine;hydron;trichloride Chemical compound Cl.Cl.Cl.NCCCCNCCCN LCNBIHVSOPXFMR-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 108010083127 phage repressor proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- HJRIWDYVYNNCFY-UHFFFAOYSA-M potassium;dimethylarsinate Chemical compound [K+].C[As](C)([O-])=O HJRIWDYVYNNCFY-UHFFFAOYSA-M 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000007100 recyclization reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/73—Expression systems using phage (lambda) regulatory sequences
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8011306 | 1980-04-03 | ||
| GB11306 | 1980-06-06 | ||
| GB8018701 | 1980-06-06 | ||
| GB18701 | 1980-06-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS56154499A JPS56154499A (en) | 1981-11-30 |
| JP2687995B2 true JP2687995B2 (ja) | 1997-12-08 |
Family
ID=26275083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56047361A Expired - Lifetime JP2687995B2 (ja) | 1980-04-03 | 1981-04-01 | Ｄｎａ配列、組替えｄｎａ分子およびヒト繊維芽細胞インターフェロン様ポリペプチドの製造方法 |
Country Status (27)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5554513A (en) * | 1979-11-21 | 1996-09-10 | Yeda Research & Development Co. Ltd. | Production of recombinant human interferon-beta2 |
| IL58765A (en) * | 1979-11-21 | 1986-09-30 | Yeda Res & Dev | Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta |
| US5510472A (en) * | 1979-11-21 | 1996-04-23 | Yeda Research And Development Co. Ltd. | Production of recombinant human interferon-beta2 |
| DK33181A (da) * | 1980-02-06 | 1981-08-07 | Searle & Co | Fremgangsmaade til fremstilling af et interferonlignende protein |
| DE3005843A1 (de) * | 1980-02-16 | 1981-09-10 | Hoechst Ag, 6000 Frankfurt | Genprodukt eines hoeheren organismus aus einem dieses gen enthaltenden mikroorganismus |
| GR74282B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1980-06-06 | 1984-06-21 | Biogen Nv | |
| EP0042246B1 (en) * | 1980-06-12 | 1987-03-18 | The Cancer Institute Of Japanese Foundation For Cancer Research | Plasmid |
| US4874702A (en) * | 1980-09-08 | 1989-10-17 | Biogen, Inc. | Vectors and methods for making such vectors and for expressive cloned genes |
| NZ198445A (en) * | 1980-09-25 | 1984-05-31 | Genentech Inc | Production of human fibroblast interferon by recombinant dna technology |
| ZA816621B (en) * | 1980-09-25 | 1982-09-29 | Genentech Inc | Microbial production of human fibroblast interferon |
| IL63327A (en) * | 1981-07-16 | 1985-11-29 | Yeda Res & Dev | Production of interferon beta1 and alpha-phage recombinants for its production in host bacteria |
| GB2108510B (en) * | 1981-10-03 | 1984-12-12 | Ciba Geigy Ag | Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof |
| JPS58110600A (ja) * | 1981-12-25 | 1983-07-01 | Kyowa Hakko Kogyo Co Ltd | ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド |
| JPS58141796A (ja) * | 1982-02-18 | 1983-08-23 | Kyowa Hakko Kogyo Co Ltd | ペプチドの製造法 |
| US4582800A (en) * | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| IL69382A (en) * | 1982-08-05 | 1991-01-31 | Carter William Alvin | Method of protecting plants against viral pathogens by inserting into plant cells genes encoding polypeptides containing interferon domains |
| US4737462A (en) * | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| FI82266C (fi) * | 1982-10-19 | 1991-02-11 | Cetus Corp | Foerfarande foer framstaellning av il-2 -mutein. |
| US4588585A (en) * | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| GR79124B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1982-12-22 | 1984-10-02 | Genentech Inc | |
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| DE3379506D1 (en) * | 1983-08-22 | 1989-05-03 | Kyowa Hakko Kogyo Kk | Process for producing peptide |
| EP0226639B1 (en) * | 1985-05-29 | 1990-11-14 | The Green Cross Corporation | Process for preparing heterogenic protein |
| WO1987000553A1 (en) * | 1985-07-16 | 1987-01-29 | The Green Cross Corporation | Process for preparing hetero-protein |
| FR2635113B1 (fr) * | 1988-08-05 | 1992-07-24 | Sanofi Sa | Procede d'obtention d'interleukine-1 (beta) mature a partir de cellules d'e. coli transformees |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5545723A (en) * | 1994-03-15 | 1996-08-13 | Biogen Inc. | Muteins of IFN-β |
| KR100711990B1 (ko) | 1997-09-23 | 2007-05-02 | 렌트슐러 비오테히놀로기 게엠베하 | 액상 인터페론-베타 제제 |
| US7144574B2 (en) | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
| US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
| US7431921B2 (en) | 1999-08-27 | 2008-10-07 | Maxygen Aps | Interferon beta-like molecules |
| US6905688B2 (en) | 2000-04-12 | 2005-06-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| MXPA03007619A (es) | 2001-02-27 | 2003-12-04 | Maxygen Aps | Nuevas moleculas similares a interferon beta. |
| PT1463751E (pt) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
| EP1594530A4 (en) | 2003-01-22 | 2006-10-11 | Human Genome Sciences Inc | HYBRID PROTEINS OF ALBUMIN |
| JP2007519422A (ja) | 2004-02-02 | 2007-07-19 | アンブレツクス・インコーポレイテツド | 修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用 |
| WO2008137471A2 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| DE102009032179A1 (de) | 2009-07-07 | 2011-01-13 | Biogenerix Ag | Verfahren zur Reinigung von Interferon beta |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1645C (da) | 1898-06-20 | Carl Christensen | Lommekniv med et i Skaftet indskydeligt Blad. | |
| US3699222A (en) | 1958-03-11 | 1972-10-17 | Nat Res Dev | Production of viral interfering substances |
| US4184917A (en) | 1974-04-01 | 1980-01-22 | Sandoz Ltd. | Process for producing a structurally modified interferon |
| NL7404589A (nl) | 1974-04-03 | 1975-10-07 | Stichting Rega V Z W | Werkwijze voor het stabiliseren van interferon. |
| GB1521032A (en) | 1974-08-08 | 1978-08-09 | Ici Ltd | Biological treatment |
| US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| FR2321298A1 (fr) * | 1975-08-01 | 1977-03-18 | Anvar | Procede de preparation de produits a activite interferon |
| US4190495A (en) | 1976-09-27 | 1980-02-26 | Research Corporation | Modified microorganisms and method of preparing and using same |
| US4264731A (en) | 1977-05-27 | 1981-04-28 | The Regents Of The University Of California | DNA Joining method |
| DE2724918A1 (de) | 1977-06-02 | 1978-12-14 | Thomae Gmbh Dr K | Gewinnung und reinigung von humaninterferon |
| CS215108B2 (en) | 1977-07-15 | 1982-07-30 | Wellcome Found | Method of making the interferrone |
| ZA782933B (en) | 1977-09-23 | 1979-05-30 | Univ California | Purification of nucleotide sequences suitable for expression in bacteria |
| US4283489A (en) | 1977-09-23 | 1981-08-11 | The Regents Of The University Of California | Purification of nucleotide sequences suitable for expression in bacteria |
| IL55892A (en) | 1977-11-08 | 1983-10-31 | Genentech Inc | Cloning vehicle for transforming microbial host to render it capable of polypeptide expression,and products therefrom |
| NZ188838A (en) | 1977-11-08 | 1982-09-14 | Genentech Inc | Dna coding for microbial expression of mammalian polypeptide recombinant microbial cloning vehicle |
| BG38166A3 (bg) | 1977-11-08 | 1985-10-15 | Genentech, Inc. | Метод за получаване на полипептид,включващ експресия на негов хетероложен ген от рекомбинантен микробен клониращ вектор |
| DE2759053A1 (de) | 1977-12-30 | 1979-07-12 | Uhlin | Verfahren zum herstellen von genprodukten von plasmid-dns |
| FR2422956A1 (fr) | 1978-04-13 | 1979-11-09 | Pasteur Institut | Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede |
| DE2961658D1 (en) | 1978-05-17 | 1982-02-18 | Thomae Gmbh Dr K | Process for preparing human interferon |
| US4322497A (en) | 1978-06-02 | 1982-03-30 | Eli Lilly And Company | Process for transducing Escherichia coli K12 χ1776 |
| US4411994A (en) | 1978-06-08 | 1983-10-25 | The President And Fellows Of Harvard College | Protein synthesis |
| US4307193A (en) | 1978-06-09 | 1981-12-22 | Toray Industries, Inc. | Method of producing interferon |
| JPS5519239A (en) | 1978-07-28 | 1980-02-09 | Green Cross Corp:The | Interferon-producing attractant |
| FI792481A7 (fi) | 1978-08-11 | 1981-01-01 | The Regents Of The Univ Of | Enkaroyyttisen proteiinin synteesi mikro-organismia käyttäen. |
| JPS5561798A (en) | 1978-10-30 | 1980-05-09 | Noda Sangyo Kagaku Kenkyusho | Preparation of novel recombination dna |
| JPS5564799A (en) | 1978-11-07 | 1980-05-15 | Toray Ind Inc | Multi-stage concentration and purification of interferon originated from human fibroblast |
| US4241174A (en) | 1978-11-24 | 1980-12-23 | Hoffmann-La Roche Inc. | Interferon assay |
| IN150740B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1978-11-24 | 1982-12-04 | Hoffmann La Roche | |
| NL8000127A (nl) | 1979-01-15 | 1980-07-17 | Harvard College | Werkwijze voor het vormen van prokaryotische of eukaryotische proteinen alsmede een daarbij toepasbaar gekoppeld gen. |
| EP0014050A3 (en) | 1979-01-16 | 1980-10-01 | Beecham Group Plc | Interferon production |
| US5326859A (en) * | 1979-10-30 | 1994-07-05 | Juridical Foundation, Japanese Foundation For Cancer Research | DNA and recombinant plasmid |
| JPS56131598A (en) | 1980-03-19 | 1981-10-15 | Japan Found Cancer | Novel recombinant plasmid having gene of human fibroblastic interferon messenger rna |
| US5514567A (en) | 1979-01-30 | 1996-05-07 | Juridical Foundation, Japanese Foundation For Cancer Research | DNA and recombinant plasmid |
| JPS5663996A (en) | 1979-10-30 | 1981-05-30 | Japan Found Cancer | Novel recombinant having gene complementary to human interferon messenger rna |
| US4357421A (en) | 1979-04-02 | 1982-11-02 | G. D. Searle & Co. | Synthetic gene coding for influenza hemagglutinin |
| FI77877C (fi) | 1979-04-20 | 1989-05-10 | Technobiotic Ltd | Foerfarande foer framstaellning och rening av human le-formig interferonprotein. |
| IL57108A (en) | 1979-04-22 | 1981-12-31 | Yeda Res & Dev | Assay for the quantitative determination of interferon and a kit therefor |
| US4293652A (en) | 1979-05-25 | 1981-10-06 | Cetus Corporation | Method for synthesizing DNA sequentially |
| GB2052516B (en) | 1979-06-01 | 1983-06-29 | Searle & Co | Plasmid vectors production and use thereof |
| US4262090A (en) | 1979-06-04 | 1981-04-14 | Cetus Corporation | Interferon production |
| WO1981000116A1 (en) | 1979-07-05 | 1981-01-22 | United States Res Corp | Method for the purification and analysis of interferon |
| ZA803943B (en) | 1979-07-31 | 1981-06-24 | Hoffmann La Roche | Homogeneous fibroblast interferon and method for manufacture thereof |
| JPS5651995A (en) | 1979-10-05 | 1981-05-09 | Green Cross Corp:The | Preparation of interferon |
| NL7907791A (nl) | 1979-10-23 | 1981-04-27 | Stichting Rega V Z W | Werkwijze voor het zuiveren van interferon. |
| AU538665B2 (en) * | 1979-10-30 | 1984-08-23 | Juridical Foundation, Japanese Foundation For Cancer Research | Human interferon dna |
| IL58765A (en) * | 1979-11-21 | 1986-09-30 | Yeda Res & Dev | Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta |
| EP0030094A1 (en) | 1979-11-30 | 1981-06-10 | Beecham Group Plc | Calcium enhanced interferon production process |
| NZ195980A (en) | 1980-01-08 | 1984-10-19 | Biogen Nv | Dna sequences,recombinant dna molecules and processes for producing leukocyte interferon-like polypeptides;pharmaceutical and veterinary compositions |
| DK33181A (da) | 1980-02-06 | 1981-08-07 | Searle & Co | Fremgangsmaade til fremstilling af et interferonlignende protein |
| GB2068970B (en) * | 1980-02-06 | 1983-06-22 | Searle & Co | Recombinant dna technique for the preparation of a protein resembling human interferon |
| IE51030B1 (en) | 1980-02-06 | 1986-09-17 | Searle & Co | Recombinant dna technique for the preparation of a protein resembling human interferon |
| DE3005843A1 (de) | 1980-02-16 | 1981-09-10 | Hoechst Ag, 6000 Frankfurt | Genprodukt eines hoeheren organismus aus einem dieses gen enthaltenden mikroorganismus |
| DE3005897A1 (de) | 1980-02-16 | 1981-09-03 | Hoechst Ag, 6000 Frankfurt | Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus |
| JPS57500408A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1980-02-25 | 1982-03-11 | ||
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US4338397A (en) | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
| DK220781A (da) | 1980-05-22 | 1981-11-23 | Deutsches Krebsforsch | Fremgangsmaade til fremstilling af interferon ii og stimulerede kloner til ydfoerelse af frmgangsmaaden |
| DE3019621C2 (de) | 1980-05-22 | 1982-08-19 | Stiftung Deutsches Krebsforschungszentrum, 6900 Heidelberg | Verfahren zur Herstellung von Interferon II. |
| JPS56167624A (en) | 1980-05-29 | 1981-12-23 | Toray Ind Inc | Method of interferon production |
| JPS571237A (en) | 1980-06-03 | 1982-01-06 | Toshiba Corp | Combined integrared circuit device |
| GR74282B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1980-06-06 | 1984-06-21 | Biogen Nv | |
| JPS575158A (en) | 1980-06-12 | 1982-01-11 | Matsushita Electric Works Ltd | Automatic resetting circuit for cpu function stopping phenomenon |
| EP0042246B1 (en) * | 1980-06-12 | 1987-03-18 | The Cancer Institute Of Japanese Foundation For Cancer Research | Plasmid |
| CH651308A5 (de) | 1980-07-01 | 1985-09-13 | Hoffmann La Roche | Interferone und deren herstellung. |
| US4357422A (en) | 1980-08-14 | 1982-11-02 | Massachusetts Institute Of Technology | Method of enhancing interferon production |
| US4874702A (en) | 1980-09-08 | 1989-10-17 | Biogen, Inc. | Vectors and methods for making such vectors and for expressive cloned genes |
| NZ198445A (en) | 1980-09-25 | 1984-05-31 | Genentech Inc | Production of human fibroblast interferon by recombinant dna technology |
| US4315852A (en) | 1980-11-26 | 1982-02-16 | Schering Corporation | Extraction of interferon from bacteria |
| JPS58201794A (ja) | 1982-05-17 | 1983-11-24 | Toray Ind Inc | ヒトインターフェロンβの濃縮精製法 |
| US4835256A (en) | 1982-09-30 | 1989-05-30 | New York University & Juridical Foundation | Human gamma interferon polypeptide having glutamine as the ninth n-terminal amino acid |
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| AU594014B2 (en) | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
| NZ212207A (en) | 1984-05-31 | 1991-07-26 | Genentech Inc | Recombinant lymphotoxin |
| EP0200425B1 (en) | 1985-04-22 | 1991-12-27 | Eli Lilly And Company | Recombinant dna expression vectors and dna compounds |
| US4892819A (en) | 1985-11-25 | 1990-01-09 | Eli Lilly And Company | Recombinant DNA expression vectors and DNA compounds that encode isopenicillin N synthetase from penicillium chrysogenum |
| EP0257994B1 (en) | 1986-08-29 | 1992-09-16 | Tonen Corporation | Dna coding for rinderpest virus antigen, its preparation and use |
| DE3642096A1 (de) | 1986-12-10 | 1988-06-16 | Boehringer Ingelheim Int | Pferde-(gamma)-interferon |
| EP0286114B1 (en) | 1987-04-09 | 1994-03-30 | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. | Reg gene and protein encoded by the gene |
| ZA887773B (en) | 1987-10-26 | 1989-07-26 | Immunex Corp | Interleukin-7 |
| US5258287A (en) | 1988-03-22 | 1993-11-02 | Genentech, Inc. | DNA encoding and methods of production of insulin-like growth factor binding protein BP53 |
| JP3393180B2 (ja) | 1998-10-22 | 2003-04-07 | シャープ株式会社 | 半導体装置の製造方法 |
-
1981
- 1981-04-01 GR GR64561A patent/GR74498B/el unknown
- 1981-04-01 IN IN188/DEL/81A patent/IN156128B/en unknown
- 1981-04-01 FI FI811008A patent/FI88175C/fi not_active IP Right Cessation
- 1981-04-01 EP EP81301414A patent/EP0041313B1/en not_active Expired - Lifetime
- 1981-04-01 AU AU68979/81A patent/AU564690B2/en not_active Expired
- 1981-04-01 IE IE756/81A patent/IE57069B1/en not_active IP Right Cessation
- 1981-04-01 ES ES500966A patent/ES8302096A1/es not_active Expired
- 1981-04-01 NZ NZ196706A patent/NZ196706A/en unknown
- 1981-04-01 HU HU81841A patent/HU193507B/hu unknown
- 1981-04-01 YU YU859/81A patent/YU45104B/xx unknown
- 1981-04-01 DE DE8181301414T patent/DE3177213D1/de not_active Revoked
- 1981-04-01 CA CA374378A patent/CA1341604C/en active Active
- 1981-04-01 JP JP56047361A patent/JP2687995B2/ja not_active Expired - Lifetime
- 1981-04-01 AT AT81301414T patent/ATE56471T1/de active
- 1981-04-01 KR KR1019810001103A patent/KR860001471B1/ko not_active Expired
- 1981-04-01 PT PT72786A patent/PT72786B/pt unknown
- 1981-04-01 IL IL62552A patent/IL62552A0/xx unknown
- 1981-04-01 DK DK148581A patent/DK170476B1/da not_active IP Right Cessation
- 1981-04-01 NO NO811118A patent/NO811118L/no unknown
- 1981-04-02 PL PL1981230484A patent/PL149079B1/pl unknown
- 1981-04-02 DD DD81228897A patent/DD160280A5/de active IP Right Maintenance
-
1985
- 1985-02-22 NO NO850735A patent/NO850735L/no unknown
- 1985-02-22 NO NO850734A patent/NO850734L/no unknown
-
1992
- 1992-06-17 MX MX9202946A patent/MX9202946A/es unknown
-
1994
- 1994-02-11 BG BG098456A patent/BG60441B2/bg unknown
-
1995
- 1995-05-25 US US08/452,658 patent/US7635466B1/en active Active
- 1995-05-25 US US08/449,930 patent/US7588755B1/en active Active
- 1995-10-12 HK HK160095A patent/HK160095A/en not_active IP Right Cessation
-
1997
- 1997-04-07 NL NL970018C patent/NL970018I1/nl unknown
- 1997-08-13 NL NL970032C patent/NL970032I2/nl unknown
- 1997-09-03 LU LU90131C patent/LU90131I2/fr unknown
Non-Patent Citations (2)
| Title |
|---|
| 「ＧＥＮＥ」 第１０巻，Ｐ．１１〜１５，１９８０年５月２１日発行 |
| 「Ｎａｔｕｒｅ」 第２８４巻，Ｐ．３１６〜３２０，１９８０年３月２７日発行 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2687995B2 (ja) | Ｄｎａ配列、組替えｄｎａ分子およびヒト繊維芽細胞インターフェロン様ポリペプチドの製造方法 | |
| JP2515308B2 (ja) | ヒト免疫インタ−フエロン | |
| SU1764515A3 (ru) | Способ получени лейкоцитарного интерферона | |
| KR940010865B1 (ko) | 종양 괴사 인자의 생산 방법 및 종양 괴사 인자의 수율을 증가시키는 방법 | |
| JP2633227B2 (ja) | 動物インターフエロン | |
| JP2559705B2 (ja) | 組換えインタ−ロイキン−１ | |
| JPS61502682A (ja) | リンホカインの生産および精製 | |
| JP2000157291A (ja) | 大きな構造遺伝子の製造および発現 | |
| JPH0630582B2 (ja) | Ｄｎａ導入ベクタ− | |
| JPH07173195A (ja) | α−インターフェロン及びその製造方法 | |
| JPH0240080B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| US4761375A (en) | Human interleukin-2 cDNA sequence | |
| EP0161901A2 (en) | Human il-1 cDNA sequences encoding biologically-active human il-1 proteins | |
| JPH064674B2 (ja) | ヒトインタ−ロイキン−１遺伝子のクロ−ニング及び特性化 | |
| JPS61129200A (ja) | 新規な白血球インタ−フエロン | |
| JPH02195888A (ja) | ヒトインターロイキン２活性を有するポリペプチドをコードする遺伝子を含有する組換えｄｎａ体および該組換えｄｎａ体により形質転換された原核生物細胞 | |
| EP0163603B1 (en) | A human t-cell growth factor | |
| JPH06102021B2 (ja) | 新規なポリペプチド | |
| JPS62215392A (ja) | ウシ・ガンマ−インタ−フエロンのクロ−ニング、同定および発現 | |
| KR890001828B1 (ko) | 인터페론-α형의 폴리펩티드의 제조방법 | |
| KR960013388B1 (ko) | 인체 면역글로불린 e 결합인자와 관련돤 폴리펩타이드, 이의 제조방법 및 이를 함유하는 약제학적 제제 | |
| JPS62151182A (ja) | 遺伝子及びその製造方法 | |
| JPS61149092A (ja) | ヒトインタ−ロイキン１をコ−ドする新規ｄｎａ | |
| Kan et al. | Expression of Human C5a in E. Coli | |
| BG60939B2 (bg) | Човешки имунен интерферон |